MedPharm, a leading contract drug development and manufacturing organization (CDMO), has officially entered into a new strategic agreement with a global pharmaceutical partner. The deal focuses on the commercial site transfer and subsequent large-scale manufacturing of a branded specialty topical pharmaceutical product, marking a significant milestone in the company’s ongoing expansion.
This partnership represents MedPharm’s fifth commercial contract secured within the last 20 months. The agreement serves as a further validation of the capabilities at the company’s state-of-the-art manufacturing facility in Durham, North Carolina, which recently successfully completed an FDA inspection for the commercial manufacture of drug products.
With nearly three decades of specialized experience, MedPharm has established itself as an industry leader in the development and manufacturing of topical, transdermal, and transepithelial drug delivery systems. Under the terms of the new agreement, MedPharm will utilize this extensive technical expertise to oversee the complex technology transfer process, ensuring the branded product is seamlessly integrated into their Durham production lines.
“We are very pleased to finalize yet another important deal this year, in this instance supporting a cornerstone client who is moving a branded specialty pharmaceutical product to our site,” said Bill Humphries, CEO of MedPharm. “We look forward to working closely with our partner to support the successful transfer of this product and help bring an important treatment option to patients who need it most.”
The financial impact of the collaboration is expected to be felt over the coming years as the product transitions from the transfer phase to full-scale commercialization. According to the company, the agreement is set to generate meaningful technology transfer revenues throughout 2026 and 2027. Once the transfer is completed, MedPharm will begin recognizing commercial manufacturing revenues starting in 2027.
The addition of this program significantly bolsters MedPharm’s growing portfolio of commercial partnerships. As the demand for sophisticated topical and transdermal therapies continues to rise, MedPharm’s ability to provide end-to-end support—from initial drug development to high-quality commercial production—positions the company as a preferred partner for global pharmaceutical entities. By facilitating this transition, MedPharm continues to demonstrate its commitment to streamlining the path to market for essential medical treatments, ensuring that high-quality specialty products reach the patients who depend on them.
The successful securing of this contract reinforces the strategic importance of the Durham facility and signals a robust outlook for MedPharm’s commercial manufacturing division as it moves toward 2027 and beyond.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
